EMAIL THIS PAGE TO A FRIEND

Expert opinion on pharmacotherapy

Fixed combination isosorbide dinitrate-hydralazine for nitric-oxide-enhancing therapy in heart failure.


PMID 17150006

Abstract

The major advances in our understanding and management of heart failure (HF) in recent decades have not fully benefited all segments of our population. HF still represents a growing epidemic, especially for African-Americans, in whom the burden of HF is even greater. The recently reported beneficial effects of the fixed combination of isosorbide dinitrate and hydralazine (ISDN+HYD) in the African-American Heart Failure Trial (A-HeFT), has led to both the FDA approval of this agent and its endorsement by the latest HF guidelines. The properties of ISDN+HYD are well known as its components are mature agents, readily available in generic formulations that have been used for decades in other indications. However, fixed-dose ISDN+HYD represents the first drug to undergo targeted clinical development and to be approved for use in a specific ethnic group. As such, A-HeFT and the approval of ISDN+HYD represent landmark events that merit further scrutiny.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

I0775000
Isosorbide dinitrate, European Pharmacopoeia (EP) Reference Standard
C6H8N2O8